BIL Gates And The BioBrick Foundation: A New Paradigm For Biotechnology? – Manufacturing.net
By Dr. Matthew Watson
![]() Manufacturing.net | BIL Gates And The BioBrick Foundation: A New Paradigm For Biotechnology? Manufacturing.net No, that's not a typo in the headline. I'm not talking about the founder of Microsoft, though he is no doubt the reason that biotechnology researcher Drew Endy decided to name his new computer-in-a-cell devices Boolean Integrase Logic gates (BIL for ... |
Another Tenderfoot – Natural History Magazine
By Dr. Matthew Watson
![]() Natural History Magazine | Another Tenderfoot Natural History Magazine With the tools of molecular genetics at our disposal, even the most common birds can reveal fascinating secrets. Since my first trip in early 2011, I have traveled to New Guinea four times. When I returned from my last trip, my fieldwork completed, I ... |
Tough Calls on Prenatal Tests – Wall Street Journal
By Dr. Matthew Watson
![]() Wall Street Journal | Tough Calls on Prenatal Tests Wall Street Journal But there is a risk that aggressive marketing based on test performance from the early clinical trials could confuse physicians and patients with complex information, said Girish Putcha, a practicing molecular-genetics pathologist and former laboratory ... |
“Patient experience with BRCA1/2 genetic testing: a thematic analysis of free … – IUPUI Newscenter
By Dr. Matthew Watson
“Patient experience with BRCA1/2 genetic testing: a thematic analysis of free ... IUPUI Newscenter April Hall, Genetics Counseling Graduate Student, Division of Clinical and Biochemical Genetics, Department of Medical and Molecular Genetics, IU School of Medicine, will present, "Patient experience with BRCA1/2 genetic testing: a thematic analysis of ... |
National Melanoma Summit media release: More public awareness of changing … – New Zealand Doctor Online
By Dr. Matthew Watson
National Melanoma Summit media release: More public awareness of changing ... New Zealand Doctor Online He says recently there have been remarkable results in treating advanced melanoma with targeted therapies based on molecular genetics - pills designed with knowledge derived from the molecular genetics revolution. "They work so well that people who are ... |
Call to equip youth with IT education – The Nation
By Dr. Matthew Watson
![]() The Nation | Call to equip youth with IT education The Nation He was delivering lecture on opportunities for Pakistani scientists in the field of medicine at the concluding session of conference organized by Department of Microbiology and Molecular Genetics. Prof Shahida Hasnain, Vice Chancellor, Women University ... |
Genetic instabilities a potential culprit for autism – Examiner.com
By Dr. Matthew Watson
![]() Examiner.com | Genetic instabilities a potential culprit for autism Examiner.com The study will be published in full in the upcoming edition of Human Molecular Genetics. According to the study, these genetic changes are caused by an overflow of DNA segments in hot spot areas, potentially affecting the possibility of a child ... |
StemCells, Inc., Rejects $20 Million from California Stem Cell Agency
By Dr. Matthew Watson
When does a financially struggling
biotech company turn down a $20 million “forgivable loan?”
Ca., and the cash is being offered by the $3 billion California stem
cell agency. The research program has handed out nearly 600 awards, and it is the first time that a recipient has rejected funding.
cell saga that began publicly last July and that involved unusual personal lobbying by the former chairman of the Golden State's stem cell research agency. The high point of the saga may have come in
September when the agency's governing board finished awarding
StemCells, Inc., $40 million in two different awards. But there was a
catch. StemCells Inc., had to match that figure with $40 million of
its own.
in the towel on the $20 million awarded on its cervical spinal cord
injury application. In comments to analysts March 21, Rodney Young,
chief financial officer of the publicly traded company, said:
“The funding would have been in the
form of a forgivable loan, however, we have elected not to borrow
these funds from CIRM(the stem cell agency).”
“You may also recall that last
September, CIRM approved a separate application under the same
disease team program for Alzheimer's disease, which was also for up
to $20 million in the form of a loan. We remain in confidential
negotiations with CIRM regarding the terms and conditions that would
attach to this loan.”
rejecting the cash, either in the conference call transcript or in
its press release.
Inc., reported continuing losses. For 2012, net losses totaled $28.5
million compared to $21.3 million in 2011. Revenue for 2012 was $1.4
million compared to $1.2 million in the previous year.
Inc., founded by Stanford's eminent researcher Irv Weissman, stirred
up a bit of a ruckus. The spinal injury award was handed out
routinely in July. Scientific reviewers gave it a score of 79 and
recommended funding. It was another matter on the Alzheimer's
application. It was scored at 61. Reviewers said it did not merit
funding. But the company publicly appealed to the full board, which sent the
application back for more examination. It was rejected again.
Nonetheless, in September, the 29-member board approved the award on
a 7-5 vote, bypassing a rival Alzheimer's application scored at 63.
It was the first time in the eight-year-history of the agency that
its board approved an application that was rejected twice by
reviewers.
lobbying by Robert Klein, former chairman of the board. Klein was
also chairman of the ballot campaign that created the agency, and
Weissman, who holds stock in StemCells, Inc., and sits on its board,
was a major fundraiser for the campaign.
Prize-winning columnist, Michael Hiltzik, wrote in October that
the process was “redolent of cronyism.” He said a
“charmed relationship” existed among StemCells, Inc., its
“powerful friends” and the stem cell agency.
Martin McGlynn, CEO of StemCells, Inc., expects “quick” action on
finally securing the cash.
the March conference call between McGlynn and analyst Kaey Nakae of
Ascendiant Capital Markets.
Nakae: “Okay. Just 2 more questions.
I guess the first one, as it relates to CIRM.
In deciding to decline the funding for spinal cord yet continuing to
pursue the funding for Alzheimer's, is there a difference in what
you're getting from them in terms of potential terms and conditions
that allow you to proceed on one and not the other, or is it the fact
that you're already in human with -- in spine, and still very
preclinical with Alzheimer's?”
McGlynn: :”I think you're very
definitely -- you're getting at some important criteria when one
considers how to fund programs whether you use debt or equity,
etcetera. So I wouldn't disagree with anything that you've outlined
or surmised. But I just would pray your indulgence until we're
finished, the negotiations with CIRM, which are coming to a close and
we expect those to resolve pretty quickly with regards to the
Alzheimer's program. And then quite frankly, we can be way more
forthcoming and way more disclosive with regards not only to our
decisions, but to our thinking.”
day. Its 52-week high is $2.67 and its 52-week low $0.59.
How to Talk About Biotechnology – Discover Magazine (blog)
By Dr. Matthew Watson
How to Talk About Biotechnology Discover Magazine (blog) It's been said before, but it bears repeating that genetic modification is little more than a new tool in the perennial human endeavor to modify the biology that surrounds us – a project that exploded with the advent of agriculture and the development ... |
USU hosting 13th annual Biotechnology Summer Academy – Cache Valley Daily
By Dr. Matthew Watson
USU hosting 13th annual Biotechnology Summer Academy Cache Valley Daily Utah State University is again offering summer laboratory experiences for high school students interested in biological sciences and engineering. The 13th annual Biotechnology Summer Academy will be held July 8-12. Summer Academy is a one-week ... |
Sign Agric Biotechnology Bill into Law, Saraki Appeals to Jonathan – THISDAY Live
By Dr. Matthew Watson
![]() THISDAY Live | Sign Agric Biotechnology Bill into Law, Saraki Appeals to Jonathan THISDAY Live Former governor of Kwara State, Senator Bukola Saraki, Wednesday urged President Goodluck Jonathan, to as a matter of urgency, assent to Agricultural Biotechnology Bill earlier passed by the two chambers of the National Assembly. Saraki, who represents ... |
SUNY Fredonia’s Ferguson earns National Science Foundation grant – Evening Observer
By Dr. Matthew Watson
![]() Evening Observer | SUNY Fredonia's Ferguson earns National Science Foundation grant Evening Observer Though not funded by the $250,000 National Science Foundation grant he just received, it will be a key instrument in his molecular genetics research. Ferguson, who earned a doctorate in genetics and gene regulation from the University of Pennsylvania ... |
DNA Testing For Cancer ‘Routine Within Five Years’29 – Huffington Post UK
By Dr. Matthew Watson
![]() New York Daily News | DNA Testing For Cancer 'Routine Within Five Years'29 Huffington Post UK Their findings appear in 13 papers in five journals, Nature Genetics, Nature Communications, PLoS Genetics, the American Journal of Human Genetics and Human Molecular Genetics. The chip used in the analysis cost just £30, and although the study relied ... Record gene haul points to better cancer screeningTimes LIVE Study gives new insight into genetic risk of breast, prostate and ovarian cancersWellcome Trust 74 genetic errors identified as markers for increased cancer riskCBS News University of Manchester -ScienceAlert -Medscape all 130 news articles » |
Scientists Use DNA to Determine Food Contents – LA Weekly (blog)
By Dr. Matthew Watson
![]() LA Weekly (blog) | Scientists Use DNA to Determine Food Contents LA Weekly (blog) Scientists at the Institute of Molecular Genetics, Genetic Security Research and Consulting at Johannes Gutenberg University in Mainz have adapted the latest techniques of DNA sequencing, which are otherwise employed in human genetics, and applied ... |
Edison inks pact with Japanese-based DSP for developing orphan mitochondrial … – pharmabiz.com
By Dr. Matthew Watson
Edison inks pact with Japanese-based DSP for developing orphan mitochondrial ... pharmabiz.com The positive clinical results of a phase II A trial of EPI - 743 in children with Leigh syndrome were recently reported in Molecular Genetics and Metabolism (EPI - 743 reverses the progression of the paediatric mitochondrial disease — Genetically ... |
More about Funding for Personalized Medicine Research
By Dr. Matthew Watson
A post entitled Funding for Personalized Medicine Research, dated January 31, 2012, provided information about the participation of the Cancer Stem Cell Consortium (CSCC) in the Large-Scale Applied Research Project Competition of Genome Canada, in collaboration with the first phase of the Personalized Medicine Signature Initiative of the Canadian Institutes of Health Research (CIHR).
On March 26, 2013, it was announced that 17 projects will be supported. A list of these project is available (PDF). One of the 17 projects is entitled "Innovative chemogenomic tools to improve outcome in acute myeloid leukemia". The Project leader is Guy Sauvageau of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal. The Project co-leader is Josée Hébert of the Centre de Recherche Hôpital Maisonneuve-Rosemont, Montréal. One of the aims of this project is to develop new models for tracking cancer stem cells that are left behind after a patient is treated.
Source:
http://cancerstemcellnews.blogspot.com/2013/03/more-about-funding-for-personalized.html
Scientists Identify Genetic Causes For Prostate, Breast And Ovarian Cancer In … – South Asia Mail
By Dr. Matthew Watson
![]() The Malaysian Insider | Scientists Identify Genetic Causes For Prostate, Breast And Ovarian Cancer In ... South Asia Mail COGS has released a batch of 13 papers in five journals this week, including: Nature Communications, Nature Genetics, PLOS Genetics, the American Journal of Human Genetic, and Human Molecular Genetics. The study will lead to a deeper understanding ... Scientists pinpoint gene coding errors for cancerThe Malaysian Insider |
Science journalist Emily Anthes explores biotech’s innovations in a new book – CNN – Canada
By Dr. Matthew Watson
Science journalist Emily Anthes explores biotech's innovations in a new book CNN - Canada The techniques of molecular genetics really lets us go in and, for the first time, target very specific individual genes. One of the big areas of interest has been in creating hypoallergenic pets. With cats, for instance, there's one gene in particular ... |
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India – Video
By Dr. Matthew Watson
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India
By: neurogenbsi
Originally posted here:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India - Video
The Super Protein That Can Cut DNA and Revolutionise Genetic Engineering – Gizmodo UK
By Dr. Matthew Watson
![]() Gizmodo UK | The Super Protein That Can Cut DNA and Revolutionise Genetic Engineering Gizmodo UK The protein, called Cas9, can be exploited to snip strands of DNA in exactly the place researchers want. It doesn't make genetic engineering easy, but does make it much, much easier — as it allows researchers to splice sequences of DNA together ... |